Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H 1) Effect of Bilastine

Clinical Pharmacokinetics

Volumn 48, Issue 8, 2009, Pages 543-554

  Jauregizar, Nerea ^a   Fuente, Leire De La ^a   Lucero, Maria Luisa ^b,d   Sologuren, Ander ^b   Leal, Nerea ^c   Rodríguez, Mónica ^c  

^a PharmaDatum Data Anlisis SL ^*  (Spain)

^b FAES SA   (Spain)

^c DynaKin SL Parque Tecnolgico de Bizkaia   (Spain)

^d FAES FARMA SA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BILASTINE; F 96221; HISTAMINE H1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; COMPUTER PROGRAM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; FEMALE; HUMAN; HUMAN EXPERIMENT; IC 50; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SIMULATION; SINGLE DRUG DOSE; STEADY STATE;

ADULT; ANTI-ALLERGIC AGENTS; BENZIMIDAZOLES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; MALE; MODELS, BIOLOGICAL; PIPERIDINES; SINGLE-BLIND METHOD;

EID: 69249136649     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11317180-000000000-00000     Document Type: Article

References (26)

1. 1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs 2005; 6: 371-87
2. Corcóstegui R, Labeaga L, Innerárity A, et al. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H, receptor antagonist. Drags 2006; 7: 219-31
3. 1 receptor antagonists. Clin Pharmacokinet 1999; 36: 329-52
4. Rosenzweig P, Caplain H, Chaufour S, et al. Comparative wheal and flare study of mizolastine vs terfenadin, Cetirizin, loratadine and placebo in healthy volunteers. Br J Clin Pharmacol 1995; 40: 459-65
5. 2 blockade on cutaneous histamine response in man. J Allergy Clin Inmunol .1980; 65: 136-9
6. Simons FER, Mc Millan JL, Simons KJ. A double-blind, single dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in healthy subjects. J Allergy Clin Inmunol 1990; 86: 540-7
7. Heykants JJP, Snoeck E, Awouters F, et al. Antihistamines. In: Van Boxtel CJ, Holford NHG, Danhof M, editors. The in vivo study of drug action, Amsterdam: Elsevier Science Publishers, 1992: 337-56
8. Devillier P, Bousquet J. Inhibition of the histamine-induced weal and flare response: a valid surrogate measure for antihistamine clinical efficacy? Clin Exp Allergy 2007; 37: 400-14
9. Kuna P, Nowacki Z, van Cauwenberge P, et al. A phase study comparing the efficacy and safety of once daily bilastine with cetirizine and placebo for the treatment of seasonal allergic rhinitis. Allergy 2007; 62: 132-3
10. Holford NHG, Sheiner LB. Understanding the concentration-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981; 6: 429-53
11. Deschamps C, Dubruc C, Mentre F, et al. Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model. Clin Pharmacol Ther 2000; 68: 647-57
12. 1) effects of cetirizine. Int J Clin Pharmacol Ther 1999; 37: 499-502
13. Roupe K, Sologuren A, Crean C, et al. The pharmacokinetics of bilastine after single and 14 days once daily administration [abstract], Basic Clin Pharmacol Toxicol 2007; 101 Suppl. 1:148
14. Sologuren A, Valiente R, Crean C, et al. Relationship of dose to inhibition of wheal and flare for 5 doses of bilastine and 10 mg cetirizine [abstract no. 69]. J Clin Pharmacol 2007; 47 (9): 1198
15. Roupe K, Sologuren A, Crean C, et al. Effect of age and gender on the pharmacokinetics and pharmacodynamics of bilastine [abstract no. 70]. J Clin Pharmacol. 2007; 47 (9): 1198
16. 1 de bilastina tras su administración única y repetida en voluntarios sanos. XIX Congress of the Spanish Society of Clinical Pharmacology; 2004 Oct 28-30; Santander
17. Sologuren. A, Crean C, Valiente R, et al. The drug-drug interaction of ketoconazole on bilastine pharmacokinetics [abstract plus poster no. 476]. Basic Clin Pharmacol Toxicol 2007; 101 Suppl. 1: 148
18. Crean C, Valiente R, Sologuren A, et al. Effect of grapefruit juice on the pharmacokinetics of bilastine [abstract no. 71]. J Clin Pharmacol 2007; 47 (9): .11.98
19. Beal SL, Boeckmann AJ, Sheiner LB, editors. NONMEM user guides. San Francisco (CA): NONMEM. Project Group, University of California, 1992
20. Levy G. Mechanism-based pharmacodynamic modelling. Clin Pharmacol Ther .1994; 56: 356-8
21. Purohit A, Melac M, Pauli G, et al. Comparative activity of cetirizine and mizolastine on histamine-induced skin wheal and flare responses at 24 h. Br J Clin Pharmacol 2002; 53: 250-4
22. Bousquet J, Chanal I, Mumeta M. et al. Lack of sensitivity to mizolastine over 8-week treatment. Allergy 1996; 51: 251-6
23. Pinquier JL, Caplain. H, Cabanis MJ, et al. Inhibition of histamine-induced skin wheal, and flare after 5 days of mizolastine. J Clin Pharmacol 1996; 36: 72-8
24. Devalia JL, De Vos C, Hanotte F, et al. A. randomized, double-blind crossover comparison among cetirizine, levocetirizine, and UCB 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy 2001; 56:50-7
25. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 21: 457-78
26. Sharma A, Jusko WJ. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clinical Pharmacol 1998; 45: 229-39